Literature DB >> 16899370

Elevated plasma triglyceride levels precede amyloid deposition in Alzheimer's disease mouse models with abundant A beta in plasma.

Braydon L Burgess1, Sean A McIsaac, Kathryn E Naus, Jeniffer Y Chan, Gavin H K Tansley, Jing Yang, Fudan Miao, Colin J D Ross, Miranda van Eck, Michael R Hayden, William van Nostrand, Peter St George-Hyslop, David Westaway, Cheryl L Wellington.   

Abstract

Dietary or pharmacological manipulation of plasma lipids markedly influences amyloid deposition in animal models of Alzheimer's Disease (AD). However, it is not known whether baseline plasma lipids in AD models differ from wild-type littermates throughout the natural history of disease. To address this question, we measured plasma total cholesterol and triglyceride levels over time in three transgenic AD mouse models in the absence of dietary or pharmacological treatments. Total cholesterol levels were not significantly different between transgenic and wild-type mice during the development of AD neuropathology in all models tested. In contrast, elevated very-low-density lipoprotein (VLDL) triglyceride levels preceded amyloid deposition in two AD models with abundant plasma A beta. Elevated triglycerides were not accompanied by increased inflammatory markers nor decreased lipase activity, but were associated with a significant 30% increase in VLDL-triglyceride secretion rate. Our results suggest that the presence of A beta in plasma may affect peripheral lipid metabolism early in AD pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16899370     DOI: 10.1016/j.nbd.2006.06.007

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  49 in total

Review 1.  Type 2 diabetes mellitus, dyslipidemia, and Alzheimer's disease.

Authors:  Cynthia M Carlsson
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

2.  Deficits in hippocampal-dependent transfer generalization learning accompany synaptic dysfunction in a mouse model of amyloidosis.

Authors:  Karienn S Montgomery; George Edwards; Yona Levites; Ashok Kumar; Catherine E Myers; Mark A Gluck; Barry Setlow; Jennifer L Bizon
Journal:  Hippocampus       Date:  2015-10-19       Impact factor: 3.899

3.  Neurometabolic roles of ApoE and Ldl-R in mouse brain.

Authors:  Jieun Lee; Joseph Choi; G William Wong; Michael J Wolfgang
Journal:  J Bioenerg Biomembr       Date:  2015-12-21       Impact factor: 2.945

4.  Three-dimensional colocalization analysis of plasma-derived apolipoprotein B with amyloid plaques in APP/PS1 transgenic mice.

Authors:  Ryusuke Takechi; Susan Galloway; Menuka Pallebage-Gamarallage; Cheryl Wellington; Russell Johnsen; John Charles Mamo
Journal:  Histochem Cell Biol       Date:  2009-02-19       Impact factor: 4.304

5.  Probucol suppresses enterocytic accumulation of amyloid-β induced by saturated fat and cholesterol feeding.

Authors:  Menuka M Pallebage-Gamarallage; Susan Galloway; Ryusuke Takechi; Satvinder Dhaliwal; John C L Mamo
Journal:  Lipids       Date:  2011-07-31       Impact factor: 1.880

6.  Mitochondrial oxidative stress-induced transcript variants of ATF3 mediate lipotoxic brain microvascular injury.

Authors:  Tun Nyunt; Monica Britton; Kwanjeera Wanichthanarak; Madhu Budamagunta; John C Voss; Dennis W Wilson; John C Rutledge; Hnin H Aung
Journal:  Free Radic Biol Med       Date:  2019-07-26       Impact factor: 7.376

7.  Amyloid-beta colocalizes with apolipoprotein B in absorptive cells of the small intestine.

Authors:  Susan Galloway; Ryusuke Takechi; Menuka M S Pallebage-Gamarallage; Satvinder S Dhaliwal; John C L Mamo
Journal:  Lipids Health Dis       Date:  2009-10-22       Impact factor: 3.876

Review 8.  The role of metabolic disorders in Alzheimer disease and vascular dementia: two roads converged.

Authors:  Suzanne Craft
Journal:  Arch Neurol       Date:  2009-03

9.  Neutralization of granulocyte macrophage colony-stimulating factor decreases amyloid beta 1-42 and suppresses microglial activity in a transgenic mouse model of Alzheimer's disease.

Authors:  Maria Manczak; Peizhong Mao; Kazuhiro Nakamura; Christopher Bebbington; Byung Park; P Hemachandra Reddy
Journal:  Hum Mol Genet       Date:  2009-07-19       Impact factor: 6.150

10.  Clozapine Improves Memory Impairment and Reduces Aβ Level in the Tg-APPswe/PS1dE9 Mouse Model of Alzheimer's Disease.

Authors:  Yura Choi; Ha Jin Jeong; Quan Feng Liu; Seung Tack Oh; Byung-Soo Koo; Yeni Kim; In-Won Chung; Yong Sik Kim; Songhee Jeon
Journal:  Mol Neurobiol       Date:  2016-01-07       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.